TY - JOUR
T1 - Advancement of pediatric blood and marrow transplantation research in North America
T2 - Priorities of the pediatric blood and marrow transplant consortium
AU - Pulsipher, Michael A.
AU - Horwitz, Edwin M.
AU - Haight, Ann E.
AU - Kadota, Richard
AU - Chen, Allen R.
AU - Frangoul, Haydar
AU - Cooper, Laurence J N
AU - Jacobsohn, David A.
AU - Goyal, Rakesh K.
AU - Mitchell, David
AU - Nieder, Michael L.
AU - Yanik, Gregory
AU - Cowan, Morton J.
AU - Soni, Sandeep
AU - Gardner, Sharon
AU - Shenoy, Shalini
AU - Taylor, Douglas
AU - Cairo, Mitchell
AU - Schultz, Kirk R.
PY - 2010/9
Y1 - 2010/9
N2 - Advances in pediatric bone marrow transplantation (BMT) are slowed by the small number of patients with a given disease who undergo transplantation, a lack of sufficient infrastructure to run early-phase oncology protocols and studies of rare nonmalignant disorders, and challenges associated with funding multi-institutional trials. Leadership of the Pediatric Blood and Marrow Transplant Consortium (PBMTC), a large pediatric BMT clinical trials network representing 77 active and 45 affiliated centers worldwide, met in April 2009 to develop strategic plans to address these issues. Key barriers, including infrastructure development and funding, along with scientific initiatives in malignant and nonmalignant disorders, cellular therapeutics, graft-versus-host disease, and supportive care were discussed. The PBMTC's agenda for approaching these issues will result in infrastructure and trials specific to pediatrics that will run through the PBMTC or its partners, the Blood and Marrow Transplant Clinical Trials Network and the Children's Oncology Group.
AB - Advances in pediatric bone marrow transplantation (BMT) are slowed by the small number of patients with a given disease who undergo transplantation, a lack of sufficient infrastructure to run early-phase oncology protocols and studies of rare nonmalignant disorders, and challenges associated with funding multi-institutional trials. Leadership of the Pediatric Blood and Marrow Transplant Consortium (PBMTC), a large pediatric BMT clinical trials network representing 77 active and 45 affiliated centers worldwide, met in April 2009 to develop strategic plans to address these issues. Key barriers, including infrastructure development and funding, along with scientific initiatives in malignant and nonmalignant disorders, cellular therapeutics, graft-versus-host disease, and supportive care were discussed. The PBMTC's agenda for approaching these issues will result in infrastructure and trials specific to pediatrics that will run through the PBMTC or its partners, the Blood and Marrow Transplant Clinical Trials Network and the Children's Oncology Group.
KW - Cooperative Group Studies
KW - Hematopoietic Stem Cell Transplantation
KW - Pediatrics
KW - Transplantation of Non-malignant Disorders
UR - http://www.scopus.com/inward/record.url?scp=77955509680&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77955509680&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2009.12.536
DO - 10.1016/j.bbmt.2009.12.536
M3 - Article
C2 - 20079865
AN - SCOPUS:77955509680
VL - 16
SP - 1212
EP - 1221
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 9
ER -